CA2251733A1 - Dhea combination therapy - Google Patents

Dhea combination therapy Download PDF

Info

Publication number
CA2251733A1
CA2251733A1 CA002251733A CA2251733A CA2251733A1 CA 2251733 A1 CA2251733 A1 CA 2251733A1 CA 002251733 A CA002251733 A CA 002251733A CA 2251733 A CA2251733 A CA 2251733A CA 2251733 A1 CA2251733 A1 CA 2251733A1
Authority
CA
Canada
Prior art keywords
interleukin
patient
group
treatment
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002251733A
Other languages
English (en)
French (fr)
Inventor
Patrick T. Prendergast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2251733A1 publication Critical patent/CA2251733A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CA002251733A 1996-04-17 1997-04-17 Dhea combination therapy Abandoned CA2251733A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1569596P 1996-04-17 1996-04-17
US60/015,695 1996-04-17

Publications (1)

Publication Number Publication Date
CA2251733A1 true CA2251733A1 (en) 1997-10-23

Family

ID=21773003

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002251733A Abandoned CA2251733A1 (en) 1996-04-17 1997-04-17 Dhea combination therapy

Country Status (9)

Country Link
EP (1) EP0901375A1 (xx)
JP (1) JP2000508654A (xx)
KR (1) KR20000005539A (xx)
CN (1) CN1216470A (xx)
AU (1) AU734807B2 (xx)
CA (1) CA2251733A1 (xx)
IL (1) IL126623A0 (xx)
NO (1) NO984851L (xx)
WO (1) WO1997038695A1 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1584A (en) * 1998-11-24 2006-03-01 Hollis Eden Pharmaceuticals Inc Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis.
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
AU775614B2 (en) * 1998-11-24 2004-08-05 Harbor Biosciences, Inc. Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other togaviruses
WO2000032176A2 (en) * 1998-11-27 2000-06-08 Hollis-Eden Pharmaceuticals, Inc. Use of 17-ketosteroids for the treatment of toxoplasmosis and cryptosporidosis
EP2983705A2 (en) * 2013-04-10 2016-02-17 Skau Aps Use of immune suppressive peptides as adjuvants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815472A1 (de) * 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
IE882585L (en) * 1988-08-25 1990-02-25 Prendergast Patrick T Viral treatment system
US5231012A (en) * 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
HU220103B (hu) * 1992-08-20 2001-10-28 Schering-Plough Corp. IL-10 új alkalmazása
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases

Also Published As

Publication number Publication date
WO1997038695A1 (en) 1997-10-23
NO984851L (no) 1998-12-17
KR20000005539A (ko) 2000-01-25
NO984851D0 (no) 1998-10-16
IL126623A0 (en) 1999-08-17
AU734807B2 (en) 2001-06-21
CN1216470A (zh) 1999-05-12
EP0901375A1 (en) 1999-03-17
AU2574197A (en) 1997-11-07
JP2000508654A (ja) 2000-07-11

Similar Documents

Publication Publication Date Title
AU2020204023B2 (en) Use of low dose IL-2 for treating autoimmune-related or inflammatory disorders
FI87733C (fi) Foerfarande foer modulering av djurcellers reaktioner in vitro med preparat innehaollande 8-substituerade guaninderivat
US20190351023A1 (en) Use of low dose il-2 for treating autoimmune - related or inflammatory disorders
Spitler et al. The Wiskott-Aldrich syndrome: results of transfer factor therapy
JPH06172183A (ja) 医薬組成物
Goodwin et al. Effect of physical stress on sensitivity of lymphocytes to inhibition by prostaglandin E2.
Gelfand et al. Partial purine nucleoside phosphorylase deficiency: Studies of lymphocyte function
Zaoui et al. Natural killer-cell function in hemodialysis patients: effect of the dialysis membrane
Coull et al. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection
Hohlfeld et al. Therapies
Morikawa et al. Immunomodulatory effect of fosfomycin on human B-lymphocyte function
Hirsch Defective autologous mixed lymphocyte reactivity in multiple sclerosis.
AU734807B2 (en) Dhea combination therapy
White et al. Immunoregulatory effects of intravenous immune serum globulin therapy in common variable hypogammaglobulinemia
WO1998047516A1 (en) Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
Stavinoha et al. Current therapy of chronic liver disease
CN112656801B (zh) 孕激素在制备治疗细胞因子释放综合征的药物中的应用
CA2255856C (en) Therapeutic uses for an aminosterol compound
Sengupta et al. In vivo effect of DDS on phytohemagglutinin (PHA)-induced lymphocyte transformation cultures in normal healthy volunteers
CN113304248B (zh) Il-2在制备缓解糖皮质激素类药物副作用的药物中的应用
Riley et al. DHEA and thymus integrity in the mouse
JPH01172345A (ja) 移植片対宿主病を防ぐための薬剤キット
Bartlett et al. Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042
EP0372541A1 (en) Method for imparting immunosuppression
BRPI0712595A2 (pt) uso de timosina alfa 1 para o tratamento de doenças imunológicas.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued